dofetilide vs placebo | No demonstrated result suggested Atrial fibrillation recurrence by 32% (not demonstrated) suggested Pro-arrhythmia by 471% (not demonstrated) | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
death or hospitalization for cardiac causes | no data | cardiovascular events | no data | Cardiovascular death | no data | myocardial infarction (fatal and non fatal) | no data | stroke (fatal and non fatal) | no data | Atrial fibrillation recurrence | 0.68 [0.47 0.97] | p=0.04 | 0 | 756 | 2 | DIAMOND,SAFIRE-D, | Cardiac nonarrhythmic death | no data | Cardiac arrhythmic death | no data | Vascular noncardiac death | no data | hospitalization for AF | no data | hospitalisation for heart failure | no data | Pro-arrhythmia | 5.71 [1.06 30.75] | p=0.04 | 0 | 756 | 2 | DIAMOND,SAFIRE-D, | All cause death | 0.97 [0.68 1.40] | p=1.00 | 0 | 756 | 2 | DIAMOND,SAFIRE-D, | non cardiovascular death | no data | Adverse events leading to treatment discontinuation | 1.68 [0.35 7.99] | p=1.00 | 0 | 250 | 1 | SAFIRE-D, | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |